Fortress Biotech (FBIO) Price/FCF Ratio: History & Chart

Fortress Biotech, Inc.(FBIO)

Biotechnology · Bay Harbor Islands, FL

$2.07-0.02 (-1.20%)

Delayed quote: Oct 6, 2026, 2:55 PM EDT

About Fortress Biotech, Inc.

Fortress Biotech, Inc. operates as a biopharmaceutical firm dedicated to the development and commercialization of a diverse range of pharmaceutical and biotechnology products. The company currently offers a portfolio of dermatological treatments. These include Ximino and Targadox, both formulated to address various forms of acne (ranging from moderate-to-severe inflammatory lesions to severe cases). Other products in this segment are Exelderm cream for fungal skin infections like ringworm and jock itch, Ceracade for dry skin conditions, Luxamend for wound care, and Accutane capsules for particularly severe, stubborn nodular acne. Its pipeline features several promising late-stage drug candidates, targeting a diverse range of medical needs. These include intravenous Tramadol for acute post-operative pain, CUTX-101 (an injection for Menkes disease), MB-107 and MB-207 for X-linked severe combined immunodeficiency, Cosibelimab for metastatic cancers, CK-101 for non-small cell lung cancer characterized by EGFR mutations, CAEL-101 for amyloid light chain (AL) amyloidosis, the Triplex vaccine for cytomegalovirus, and CEVA101 for critical traumatic brain injuries in adults and children. Furthermore, its earlier-stage research encompasses various investigational treatments such as MB-102 for blastic plasmacytoid dendritic cell neoplasm, MB-101 for glioblastoma, MB-104 for multiple myeloma and light chain amyloidosis, MB-106 for B-cell non-Hodgkin lymphoma, MB-103 for glioblastoma and metastatic breast cancer to the brain, MB-108, MB-105 for prostate and pancreatic malignancies, and BAER-101. In the preclinical phase, Fortress Biotech is exploring an array of novel therapeutic approaches. These comprise AAV-ATP7A and AVTS-001 (both gene-based therapies), the CK-103 BET inhibitor, CEVA-D and CEVA-102, CK-302 (an antibody targeting GITR), CK-303 (an antibody against CAIX), ConVax, and the ONCOlogues oligonucleotide platform. The company also actively engages in collaborative ventures with universities, research institutions, and other pharmaceutical organizations. Originally established in 2006, the entity operated as Coronado Biosciences, Inc. before rebranding as Fortress Biotech, Inc. in April 2015. Its corporate headquarters are situated in Bay Harbor Island, New York.

Bay Harbor Islands, FL

78 employees

www.fortressbiotech.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Lindsay A. Rosenwald

View full financials

FBIO Price/FCF Ratio Metrics

PRICE/FCF RATIO

0.55

PRICE/FCF RATIO AVG TTM

N/A

PRICE/FCF RATIO AVG 3Y

N/A

PRICE/FCF RATIO AVG 5Y

N/A

PRICE/FCF RATIO AVG 10Y

N/A

PRICE/FCF RATIO AVG 15Y

N/A

PRICE/FCF RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

N/A

CURRENT VS 3Y AVG

N/A

CURRENT VS 5Y AVG

N/A

CURRENT VS 10Y AVG

N/A

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

21.13

median of 208 covered companies

CURRENT VS SECTOR MEDIAN

-97.40%

vs the sector median at left

NAME	MARKET CAP	PRICE/FCF RATIO	TTM	3Y	5Y
Fortress Biotech, Inc. (FBIO)	$68.60M	0.55	N/A	N/A	N/A
Tiziana Life Sciences Ltd (TLSA)vs ›	$68.08M	N/A	N/A	N/A	N/A
Champions Oncology, Inc. (CSBR)vs ›	$68.08M	N/A	17.09	24.44	36.17
Spero Therapeutics, Inc. (SPRO)vs ›	$68.61M	3.50	11.66	7.20	7.81
Cingulate Inc. (CING)vs ›	$66.77M	N/A	N/A	N/A	N/A
iBio, Inc. (IBIO)vs ›	$66.56M	N/A	N/A	N/A	N/A
XBiotech Inc. (XBIT)vs ›	$65.88M	N/A	4.54	4.54	4.54
MindWalk Holdings Corp. (HYFT)vs ›	$71.89M	N/A	1291.26	1291.26	1291.26
Verrica Pharmaceuticals Inc. (VRCA)vs ›	$72.32M	N/A	N/A	N/A	N/A
Gain Therapeutics, Inc. (GANX)vs ›	$72.09M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

PRICE/FCF RATIO

TTM

Fortress Biotech, Inc. (FBIO)

$68.60M

0.55

N/A

Tiziana Life Sciences Ltd (TLSA)vs ›

$68.08M

N/A

Champions Oncology, Inc. (CSBR)vs ›

$68.08M

N/A

17.09

24.44

36.17

Spero Therapeutics, Inc. (SPRO)vs ›

$68.61M

3.50

11.66

7.20

7.81

Cingulate Inc. (CING)vs ›

$66.77M

N/A

iBio, Inc. (IBIO)vs ›

$66.56M

N/A

XBiotech Inc. (XBIT)vs ›

$65.88M

N/A

4.54

MindWalk Holdings Corp. (HYFT)vs ›

$71.89M

N/A

1291.26

Verrica Pharmaceuticals Inc. (VRCA)vs ›

$72.32M

N/A

Gain Therapeutics, Inc. (GANX)vs ›

$72.09M

N/A

Price/FCF Ratio FAQ

What is the Price/FCF ratio for Fortress Biotech, Inc. (FBIO)?

The Price/FCF ratio for FBIO stock is 0.55.

Is Fortress Biotech, Inc.'s Price/FCF ratio high or low?

The Price/FCF ratio of 0.55 is 25% below its estimated 1-year average of 0.74, near the low end of its estimated 1-year range (0.55–0.91).

DATE	PRICE/FCF RATIO
2026-10-05	0.61
2026-10-02	0.60
2026-10-01	0.61
2026-09-30	0.63
2026-09-29	0.65
2026-09-28	0.64
2026-09-25	0.67
2026-09-24	0.67
2026-09-23	0.69
2026-09-22	0.72
2026-09-21	0.71
2026-09-18	0.74
2026-09-17	0.74
2026-09-16	0.72
2026-09-15	0.73
2026-09-14	0.74
2026-09-11	0.74
2026-09-10	0.76
2026-09-09	0.77
2026-09-08	0.80
2026-09-04	0.80
2026-09-03	0.80
2026-09-02	0.80
2026-09-01	0.79
2026-08-31	0.81
2026-08-28	0.81
2026-08-27	0.82
2026-08-26	0.83
2026-08-25	0.83
2026-08-24	0.86
2026-08-21	0.84
2026-08-20	0.81
2026-08-19	0.84
2026-08-18	0.86
2026-08-17	0.83
2026-08-14	0.86
2026-08-13	0.73
2026-08-12	0.67
2026-08-11	0.64
2026-08-10	0.67
2026-08-07	0.65
2026-08-06	0.67
2026-08-05	0.68
2026-08-04	0.66
2026-08-03	0.67
2026-07-31	0.76
2026-07-30	0.80
2026-07-29	0.82
2026-07-28	0.83
2026-07-27	0.80
2026-07-24	0.81
2026-07-23	0.84
2026-07-22	0.87
2026-07-21	0.86
2026-07-20	0.81
2026-07-17	0.82
2026-07-16	0.83
2026-07-15	0.90
2026-07-14	0.91
2026-07-13	0.80
2026-07-10	0.80
2026-07-09	0.80
2026-07-08	0.73
2026-07-07	0.73
2026-07-06	0.72
2026-07-02	0.74
2026-07-01	0.75
2026-06-30	0.75
2026-06-29	0.72
2026-06-26	0.67
2026-06-25	0.74
2026-06-24	0.77
2026-06-23	0.77
2026-06-22	0.75
2026-06-18	0.73
2026-06-17	0.75
2026-06-16	0.71
2026-06-15	0.70
2026-06-12	0.67
2026-06-11	0.67
2026-06-10	0.67
2026-06-09	0.71
2026-06-08	0.69
2026-06-05	0.65
2026-06-04	0.67
2026-06-03	0.64
2026-06-02	0.65
2026-06-01	0.63
2026-05-29	0.68
2026-05-28	0.68
2026-05-27	0.67
2026-05-26	0.66
2026-05-22	0.67
2026-05-21	0.68
2026-05-20	0.65
2026-05-19	0.62
2026-05-18	0.60
2026-05-15	0.59

DATE

PRICE/FCF RATIO

2026-10-05

0.61

2026-10-02

0.60

2026-10-01

0.61

2026-09-30

0.63

2026-09-29

0.65

2026-09-28

0.64

2026-09-25

0.67

2026-09-24

0.67

2026-09-23

0.69

2026-09-22

0.72

2026-09-21

0.71

2026-09-18

0.74

2026-09-17

0.74

2026-09-16

0.72

2026-09-15

0.73

2026-09-14

0.74

2026-09-11

0.74

2026-09-10

0.76

2026-09-09

0.77

2026-09-08

0.80

2026-09-04

0.80

2026-09-03

0.80

2026-09-02

0.80

2026-09-01

0.79

2026-08-31

0.81

2026-08-28

0.81

2026-08-27

0.82

2026-08-26

0.83

2026-08-25

0.83

2026-08-24

0.86

2026-08-21

0.84

2026-08-20

0.81

2026-08-19

0.84

2026-08-18

0.86

2026-08-17

0.83

2026-08-14

0.86

2026-08-13

0.73

2026-08-12

0.67

2026-08-11

0.64

2026-08-10

0.67

2026-08-07

0.65

2026-08-06

0.67

2026-08-05

0.68

2026-08-04

0.66

2026-08-03

0.67

2026-07-31

0.76

2026-07-30

0.80

2026-07-29

0.82

2026-07-28

0.83

2026-07-27

0.80

2026-07-24

0.81

2026-07-23

0.84

2026-07-22

0.87

2026-07-21

0.86

2026-07-20

0.81

2026-07-17

0.82

2026-07-16

0.83

2026-07-15

0.90

2026-07-14

0.91

2026-07-13

0.80

2026-07-10

0.80

2026-07-09

0.80

2026-07-08

0.73

2026-07-07

0.73

2026-07-06

0.72

2026-07-02

0.74

2026-07-01

0.75

2026-06-30

0.75

2026-06-29

0.72

2026-06-26

0.67

2026-06-25

0.74

2026-06-24

0.77

2026-06-23

0.77

2026-06-22

0.75

2026-06-18

0.73

2026-06-17

0.75

2026-06-16

0.71

2026-06-15

0.70

2026-06-12

0.67

2026-06-11

0.67

2026-06-10

0.67

2026-06-09

0.71

2026-06-08

0.69

2026-06-05

0.65

2026-06-04

0.67

2026-06-03

0.64

2026-06-02

0.65

2026-06-01

0.63

2026-05-29

0.68

2026-05-28

0.68

2026-05-27

0.67

2026-05-26

0.66

2026-05-22

0.67

2026-05-21

0.68

2026-05-20

0.65

2026-05-19

0.62

2026-05-18

0.60

2026-05-15

0.59

Price/FCF Ratio: 0.55

FBIO Price/FCF Ratio Chart

FBIO Price/FCF Ratio Metrics

FBIO Competitors' Price/FCF Ratio

Free Cash Flow Valuation

Price/FCF Ratio Formula & Definition

Price/FCF Ratio FAQ

FBIO Price/FCF Ratio History

Related Metrics